TABLE 1. Clinical and Procedural Characteristics of Study Patients

CharacteristicIopamidol-370 Group (n=204)Iodixanol-320 Group (n=210)P*
Data are presented as mean±SD where appropriate.
*t test for continuous variables; Fisher exact test for categorical variables.
Age, y72.4±9.070.5±9.90.04
Gender, M/F138/66127/830.15
Body weight, kg82.7±17.786.7±20.60.03
Body mass index, kg/m229.2±5.330.2±5.80.06
Contrast volume, mL133.7±74.4136.4±71.60.70
Dose/body weight, gI/kg0.62±0.360.53±0.310.01
Diabetes mellitus, n (%)78 (38.2)92 (43.8)0.27
Time of postdose sampling, n (%)
    45 to 71 hours170 (83.3)175 (83.3)0.94
    71 to 96 hours27 (13.2)29 (13.8)
    >96 hours7 (3.5)6 (2.9)
Type of procedure, n (%)
    Dx cardioangiography123 (60.3)128 (61.0)0.92
    PCI81 (39.7)82 (39.0)
NAC premedication, n (%)79 (38.7)89 (42.4)0.48
Intravenous volume supplementation/body weight (mL/kg)11.2±2.311.5±2.30.32
Predose eGFR (mL/min per 1.73 m2), n (%)
    20 to 3015 (7.4)17 (8.1)0.83
    30 to 4042 (20.6)40 (19.1)
    40 to 5082 (40.1)78 (37.1)
    50 to 5965 (31.9)75 (35.7)